<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566241</url>
  </required_header>
  <id_info>
    <org_study_id>IGF-1 in Cystic Fibrosis</org_study_id>
    <nct_id>NCT00566241</nct_id>
  </id_info>
  <brief_title>IGF-1 Therapy in Patients With Cystic Fibrosis</brief_title>
  <official_title>An Investigation Into the Use of IGF-1 Therapy in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      28 week pilot study to examine the efficacy of recombinant human IGF-1 on body weight and
      composition in adults with cystic fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      28 week, double blind, cross over study to determine the efficacy of rhIGF-1 on body weight
      and body composition in patients with cystic fibrosis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight and body composition</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbohydrate tolerance</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>IGF-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human IGF-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human IGF-1</intervention_name>
    <description>rhIGF-1</description>
    <arm_group_label>IGF-1</arm_group_label>
    <other_name>mecasermin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cystic fibrosis as proven by either sweat chloride or DNA analysis.

          -  Age &gt;= 18 yr.

          -  Tanner stage: Femake Breasts: 4-5 Male Genitalia: 4-5

        Exclusion criteria:

          -  Hemoglobin A1C &gt; 8.5 %

          -  Diabetic retinopathy

          -  Obstructive sleep apnea

          -  Respiratory failure requiring mechanical ventilation.

          -  Status post pulmonary transplantation.

          -  Concurrent or recent (within past 6 months) receipt of human growth hormone.

          -  History of adverse side effects to growth hormone other than carbohydrate intolerance.

          -  Pregnancy or attempting pregnancy.

          -  Women who are breast feeding.

          -  Sexually active women who refuse to use or are incapable of responsibly using reliable
             contraception.

          -  Proven non compliance with medical regimens.

          -  Inability or refusal to take subcutaneous injections.

          -  Known allergy to components in the IGF-I preparation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Univeristy of New York, Stony Brook, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State University of New York</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Thomas A. Wilson</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Body weight</keyword>
  <keyword>Body composition</keyword>
  <keyword>Pulmonary function</keyword>
  <keyword>Carbohydrate tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

